Key points are not available for this paper at this time.
Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.
Jelı́nek et al. (Mon,) studied this question.